On November 29, 2023 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry B. González Convention Center in San Antonio, Texas (Press release, Cogent Biosciences, NOV 29, 2023, View Source [SID1234638040]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details
The posters will be available on the ‘Posters and Publications’ page of Cogent’s website when they are presented.

Presentation ID: PO3-26-02
Title: Identification of a novel, brain penetrant, EGFR sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutations
Session: Poster Session 3
Date: Thursday, December 7, 2023
Time: 12:00 PM – 2:00 PM CT (1:00 PM – 3:00 PM ET)

Presentation ID: PO3-26-01
Title: Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Kα H1047R mutant-selective inhibitor
Session: Poster Session 3
Date: Thursday, December 7, 2023
Time: 12:00 PM – 2:00 PM CT (1:00 PM – 3:00 PM ET)